Status
Conditions
Treatments
About
This study will test the safety and efficacy of the Vessix Renal Denervation system in the reduction of pain in patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD).
Full description
This study will employ the Vessix Renal Denervation System (Boston Scientific) to ablate the renal nerve by radio-ablation in patients suffering from severe pain due to Autosomal Dominant Polycystic Kidney Disease (ADPKD). Twenty patients with opiate-dependent, Autosomal Dominant Polycystic Kidney Disease-associated kidney pain will be selected to this double-blind, prospective device study. Subjects will be randomly assigned to an experimental (those who will receive nerve ablation) or control (those who will have a sham procedure in which the ablation device is not turned on) groups. Subjects will complete physical exams and be administered questionnaires regarding their mental status and pain before, during and after the denervation procedure. Renal function and adverse events will be monitored for 1 year after denervation.
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Individual has renal artery anatomy that is ineligible for treatment including:
The presence of diabetes mellitus
Individual has had ≥ 1 episode(s) of orthostatic hypotension not related to medication changes (reduction of systolic blood pressure of ≥20 mmHg or diastolic blood pressure of ≥10 mmHg within 3 minutes of standing), coupled with symptoms, within the past year or during the screening process.
Change in systolic blood pressure associated with symptoms of orthostasis
Individual requires chronic oxygen support or mechanical ventilation other than nocturnal respiratory support for sleep apnea.
The presence of primary pulmonary hypertension
The presence of other known secondary forms of hypertension such as pheochromocytoma, Cushing's Disease (adrenal insufficiency), primary hyperaldosteronism, coarctation of the aorta.
Individual has experienced a myocardial infarction within 3 months of the screening period, or has experienced unstable angina pectoris, syncope, or a cerebrovascular accident within 3 months of the screening period.
Individual has a scheduled or planned surgery within 1 year of study enrollment
Inability to complete protocol blood pressure measurements (e.g., arm diameter too large for the cuff).
Individual has severe cardiac valve stenosis for which, in the opinion of the investigator, a significant reduction of blood pressure is contraindicated.
Subjects on beta blockers and or clonidine
Individual has a confounding medical condition, which in the opinion of the investigator, may adversely affect the safety of the participant (e.g., significant peripheral vascular disease, abdominal aortic aneurysm, severe chronic obstructive pulmonary disorder)
Significant bleeding diathesis (thrombocytopenia, hemophilia, or significant anemia)
Individual is pregnant, nursing or planning to get pregnant within two years of study enrollment.
Individual has a known unresolved history of drug use or alcohol dependency, who in the opinion of the Principal Investigator lacks the ability to comprehend or follow instructions, or would be unlikely or unable, in the opinion of the investigator, to comply with study follow-up requirements
Individual with a previous solid organ transplant
Individual who has had a celiac plexus block or splanchnic nerve block for pain relief Transcutaneous electrical nerve stimulation (TENS), spinal cord stimulation, acupuncture or the use of medical marijuana for pain relief within the past 3 months
Hospitalization for non-pain related conditions within the past 3 months
Surgical treatment for ADPKD pain relief in the past 24 months (Cyst aspiration, sclerotherapy and cyst fenestration surgery)
Individuals with significant kidney stones (> 7-8 mm) on imaging studies
Subjects with acute kidney Injury in the past 6 months
Subjects with significant renal impairment (defined as glomerular filtration rate < 30 ml/min/1.73m2 determined by chronic kidney disease equation
Individual is a participant in another interventional clinical trial
Subjects with an additional accessory renal vessel that perfuses more than 25% of the kidney
Individuals with terminal illness with expected survival of less than 1 year
Current symptoms of cerebral hypoperfusion (e.g. dizziness or lightheadedness, visual blurring or darkening of the visual fields, syncope).
Acute coronary syndrome (by standard criteria) within the prior month (established by biomarkers of myocardial anatomy and/or electrocardiogram changes
Coronary revascularization procedures within 30 days of screening, or, expected procedures within the next 6 months.
Valve surgery within 30 days of screening, or, expected procedures within the next 6 months.
Cardiac resynchronization therapy, with or without implantable cardiac defibrillator within 90 days of screening or expected procedures within the next 6 months.
Hypertrophic or restrictive cardiomyopathy
Constrictive pericarditis
Active myocarditis or endocarditis
Complex congenital heart disease
Severe, advanced heart failure
Primary purpose
Allocation
Interventional model
Masking
0 participants in 2 patient groups
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal